17 . July , 2018 - Tuesday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Methergine

Big Image
Generic Name: methylergonovine maleate
Dosage Form: Tablets, usp and injection, usp

T2004-33

89009005

      Methergine®

      (methylergonovine maleate)

      Tablets, USP

      (methylergonovine maleate)

      Injection, USP

      Rx only

Methergine Description

Methergine® (methylergonovine maleate) is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage.

      Methergine® (methylergonovine maleate) is available in sterile ampuls of 1 mL, containing 0.2 mg methylergonovine maleate for intramuscular or intravenous injection and in tablets for oral ingestion containing 0.2 mg methylergonovine maleate.

Tablets

Active Ingredient: methylergonovine maleate, USP, 0.2 mg.

Inactive Ingredients: acacia, carnauba wax, D&C Red #7, FD&C Blue #1, gelatin special, lactose, maleic acid, mixed parabens, povidone, sodium benzoate, sodium hydroxide, starch, stearic acid, sucrose, talc, and titanium dioxide.

Ampuls, 1 mL, clear, colorless solution.

Active Ingredient: methylergonovine maleate, USP, 0.2 mg.

Inactive Ingredients: maleic acid, 0.10 mg; sodium chloride, 7.0 mg; water for injection, qs to 1 mL.

      Chemically, methylergonovine maleate is designated as ergoline-8-carboxamide, 9,10-didehydro-N-[1-(hydroxymethyl)propyl]-6-methyl-, [8β(S)]-, (Z)-2-butenedioate (1:1) (salt).

      Its structural formula is:

C20H25N3O2•C4H4O4 Mol. wt. – 455.51

Methergine - Clinical Pharmacology

Methergine® (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes.

      Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses. During delivery, with intramuscular injection, bioavailability increased to 78%. Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.

      Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours. For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg. When given intramuscularly, the extent of absorption of Methergine® (methylergonovine maleate) solution was about 25% greater than the tablet. The volume of distribution (Vdss/F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour. The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours). A delayed gastrointestinal absorption (Tmax about 3 hours) of Methergine® (methylergonovine maleate) tablet might be observed in postpartum women during continuous treatment with this oxytocic agent.

Indications and Usage for Methergine

For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder.

Contraindications

Hypertension; toxemia; pregnancy; and hypersensitivity.

Warnings

This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, Methergine® (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.

Precautions

General

Caution should be exercised in the presence of sepsis, obliterative vascular disease, hepatic or renal involvement. Also use with caution during the second stage of labor. The necessity for manual removal of a retained placenta should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation.

Drug Interactions

CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors)

There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine.

      No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known.

      Caution should be exercised when Methergine® (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies have been performed in animals to evaluate carcinogenic potential. The effect of the drug on mutagenesis or fertility has not been determined.

Pregnancy

Category C. Animal reproductive studies have not been conducted with Methergine® (methylergonovine maleate). It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of Methergine® (methylergonovine maleate) is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE.)

Labor and Delivery

The uterotonic effect of Methergine® (methylergonovine maleate) is utilized after delivery to assist involution and decrease hemorrhage, shortening the third stage of labor.

Nursing Mothers

Methergine® (methylergonovine maleate) may be administered orally for a maximum of 1 week postpartum to control uterine bleeding. Recommended dosage is 1 tablet (0.2 mg) 3 or 4 times daily. At this dosage level a small quantity of drug appears in mothers’ milk. Caution should be exercised when Methergine® (methylergonovine maleate) is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Clinical studies of Methergine did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Adverse Reactions

The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Nausea and vomiting have occurred occasionally. Rarely observed reactions have included, in order of severity: acute myocardial infarction, transient chest pains, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, and foul taste.1

      There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product.

Drug Abuse and Dependence

Methergine® (methylergonovine maleate) has not been associated with drug abuse or dependence of either a physical or psychological nature.

Overdosage

Symptoms of acute overdose may include: nausea, vomiting, abdominal pain, numbness, tingling of the extremities, rise in blood pressure, in severe cases followed by hypotension, respiratory depression, hypothermia, convulsions, and coma.

      Because reports of overdosage with Methergine® (methylergonovine maleate) are infrequent, the lethal dose in humans has not been established. The oral LD50 (in mg/kg) for the mouse is 187, the rat 93, and the rabbit 4.5.2 Several cases of accidental Methergine® (methylergonovine maleate) injection in newborn infants have been reported, and in such cases 0.2 mg represents an overdose of great magnitude. However, recovery occurred in all but one case following a period of respiratory depression, hypothermia, hypertonicity with jerking movements, and, in one case, a single convulsion.

      Also, several children 1-3 years of age have accidentally ingested up to 10 tablets (2 mg) with no apparent ill effects. A postpartum patient took 4 tablets at one time in error and reported paresthesias and clamminess as her only symptoms.

      Treatment of acute overdosage is symptomatic and includes the usual procedures of:

  1. removal of offending drug by inducing emesis, gastric lavage, catharsis, and supportive diuresis.
  2. maintenance of adequate pulmonary ventilation, especially if convulsions or coma develop.
  3. correction of hypotension with pressor drugs as needed.
  4. control of convulsions with standard anticonvulsant agents.
  5. control of peripheral vasospasm with warmth to the extremities if needed.3

Methergine Dosage and Administration

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

Intramuscularly

1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.

Intravenously

Dosage same as intramuscular. (See WARNINGS.)

Orally

One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

How is Methergine Supplied

Tablets

0.2 mg round, coated, orchid, branded “78-54” one side, “SANDOZ” other side.

      Bottles of 100…………………………………………………………..NDC 0078-0054-05

Ampuls

1 mL size

      Boxes of 20…………………………………………………………….NDC 0078-0053-03

Store and Dispense

Tablets: Store below 25°C (77°F); in tight, light-resistant container.

Ampuls: Store in refrigerator, 2ºC-8°C (36°F-46°F). Protect from light. Administer only if solution is clear and colorless.

References

  1. Information on Adverse Reactions supplied by Medical Services Dept., Novartis Pharmaceuticals, E. Hanover, N.J., based on computerized clinical reports.
  2. Berde, B. and Schild, H.O.: Ergot Alkaloids and Related Compounds, Springer-Verlag, New York, 1978, p. 810.
  3. Treatment of Acute Overdosage. Novartis Consumer Health, Inc. Rx Products. Novartis, Medical Services Department.

T2004-33

REV: MAY 2004                                              89009005

Distributed by:

Novartis Pharmaceuticals Corporation

East Hanover, New Jersey 07936

© Novartis


Methergine (methylergonovine maleate)
PRODUCT INFO
Product Code 0078-0054 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
methylergonovine maleate (methylergonovine) Active 0.2 MILLIGRAM  In 1 TABLET
acacia Inactive  
carnauba wax Inactive  
D&C Red #7 Inactive  
FD&C Blue #1 Inactive  
gelatin special Inactive  
lactose Inactive  
maleic acid Inactive  
mixed parabens Inactive  
povidone Inactive  
sodium benzoate Inactive  
sodium hydroxide Inactive  
starch Inactive  
stearic acid Inactive  
sucrose Inactive  
talc Inactive  
titanium dioxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color PURPLE (orchid) Score 1
Shape ROUND Symbol false
Imprint Code 78-54;SANDOZ Coating true
Size 6mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0078-0054-05 100 TABLET In 1 BOTTLE None

Methergine (methylergonovine maleate)
PRODUCT INFO
Product Code 0078-0053 Dosage Form INJECTION, SOLUTION
Route Of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
methylergonovine maleate (methylergonovine) Active 0.2 MILLIGRAM  In 1 MILLILITER
maleic acid Inactive 0.1 MILLIGRAM  In 1 MILLILITER
sodium chloride Inactive 7.0 MILLIGRAM  In 1 MILLILITER
water Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0078-0053-03 20 AMPULE In 1 BOX contains a AMPULE
1 1 MILLILITER In 1 AMPULE This package is contained within the BOX (0078-0053-03)

Revised: 08/2006

Recent Drug Updates at DrugIndexOnline:





Americaine Otic Drops Americaine Otic Drops
Generic Name: Benzocaine Ear Drops (BEN-zoe-kane) Brand Name: Examples include Americaine Otic and OtocainAmericaine Otic Drops is used for:Relieving pain and itching in the ear caused by ear infections. It may also be used for other conditions as determined by your doctor. Americaine Otic Drop more...

Cerubidine Cerubidine
Some commonly used brand names are: In the U.S.— Cerubidine In Canada— Cerubidine Category Antineoplastic Description Daunorubicin (daw-noe-ROO-bi-sin) belongs to the general group of medicines known as antineoplastics. It is used to treat some kinds of cancer. Daunorubic more...

Crestor Crestor
Generic name: Rosuvastatin calcium Brand names: Crestor Why is Crestor prescribed? Crestor is used to lower cholesterol levels when diet and exercise alone have failed to work. The drug can help lower the total cholesterol count as well as harmful levels of low-density lipoprotein (LDL) choleste more...

Erybid Erybid
Some commonly used brand names are: In the U.S.— E-Base 1 E-Mycin 1 ERYC 1 Ery-Tab 1 E.E.S. 3 EryPed 3 Erythro 3 Erythrocin 6 Erythrocot 6 Ilotycin 1 Ilosone 2 My-E 6 PCE 1 Wintrocin 6 In Canada— Apo-Erythro 1 Apo-Erythro E-C 1 Apo-Erythro-ES 3 Apo-Erythro-S 6 E-Mycin 1 E.E.S. 3 E more...

KGS-PE Liquid KGS-PE Liquid
Generic Name: Phenylephrine/Potassium Guaiacolsulfonate Liquid (fen-ill-EF-rin/poe-TASS-ee-uhm gwie-ah-kole-SULL-foe-nate) Brand Name: KGS-PEKGS-PE Liquid is used for:Relieving symptoms of congestion, cough, and throat and airway irritation due to colds, flu, or hay fever. It may also be used fo more...

L-Methylfolate/B12/B6/B2 L-Methylfolate/B12/B6/B2
Generic Name: L-Methylfolate/B12/B6/B2 (Vitamins) Tablets (meth-ill-FOE-late) Brand Name: CerefolinL-Methylfolate/B12/B6/B2 is used for:Managing hyperhomocysteinemia or to supplement the diet. It may also be used to treat other conditions as determined by your doctor. L-Methylfolate/B12/B6/B2 more...

Levobunolol Ophthalmic Levobunolol Ophthalmic
Some commonly used brand names are: In the U.S.— AKBeta 4 Betagan 4 Betaxon 3 Betimol 6 Betoptic 1 Betoptic S 1 Ocupress 2 OptiPranolol 5 Timoptic 6 Timoptic in Ocudose 6 Timoptic-XE 6 In Canada— Apo-Timop 6 Betagan 4 Betoptic S 1 Novo-Levobunolol 4 Novo-Timol 6 Ophtho-Bunolol 4 T more...

Periactin Periactin
Generic Name: cyproheptadine (sip row HEP ta deen) Brand Names: Periactin What is Periactin (cyproheptadine)? Cyproheptadine is an antihistamine. Cyproheptadine blocks the effects of the naturally occurring chemical histamine in your body. Cyproheptadine is used to treat sneezing; runny more...